PlasmaGen Biosciences, a biopharmaceutical company based in Bengaluru, has raised Rs 150 crore with the help of ViNS Bioproducts, high-net-worth individuals, family offices, pharmaceutical entrepreneurs, and current investors. Eight Road Ventures, the startup’s backer, raised the money at a valuation of more than Rs 1,500 crore.
Fidelity’s FIL Capital Investments, Eight Roads Ventures, F-Prime Capital, and others have contributed more than Rs 600 crore to PlasmaGen thus far.
According to a press release from PlasmaGen Biosciences, the proceeds will be utilized to boost manufacturing and leadership capabilities, broaden the product portfolio, and scale international operations.
PlasmaGen Biosciences was established in 2010 with the goal of becoming self-sufficient in plasma products. It operates a state-of-the-art fractionation plant in Kolar, Karnataka, and serves neurology, hematology, and critical care by manufacturing and marketing plasma-derived therapies such as immunoglobulin, albumin, and clotting factors to close the gap between supply and demand for these essential medicines in India.
PlasmaGen claims that it is in the process of obtaining regulatory approvals to start international sales and has found distribution partners in important export regions. India is still a major market for the company, which is using a cold-chain-backed distribution network to expand its services among hospitals and doctors.
According to PlasmaGen, commercial operations at its plasma fractionation plant in Kolar, close to Bengaluru, started in 2024. The company claims that it is the first pure-play plasma biopharma player, that it is one of only five such facilities in the nation, that it has seen significant revenue growth since starting operations at Kolar, and that it is currently getting ready to enter international markets.
